Related Experiment Video

Updated: May 28, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

CD30-targeted antibody therapy

Anas Younes1

  • 1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. ayounes@mdanderson.org

Current Opinion in Oncology
|October 12, 2011
PubMed
Abstract

Insights

Brentuximab vedotin shows significant promise for treating CD30+ cancers like Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). This antibody-drug conjugate offers potent single-agent activity in relapsed cases.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Therapeutic targeting of CD30+ cancers has historically involved naked and conjugated monoclonal antibodies.
  • Early trials with anti-CD30 antibodies yielded unsuccessful outcomes.
  • Development of antibody-drug conjugates represents a significant advancement in targeting CD30+ malignancies.

Purpose of the Study:

  • To review current knowledge on therapeutic strategies for CD30+ cancers.
  • To evaluate the efficacy of naked and conjugated monoclonal antibodies, including antibody-drug conjugates.

Main Methods:

  • Review of existing literature and clinical trial data on CD30-targeting antibodies.
  • Analysis of Phase II study results for brentuximab vedotin in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).
  • Assessment of regulatory recommendations for accelerated approval.

Main Results:

  • Brentuximab vedotin, an antibody-drug conjugate, demonstrated substantial progress after earlier trials' unsuccessful outcomes.
  • Phase II studies showed high single-agent response rates: 75% in relapsed Hodgkin lymphoma and 86% in systemic ALCL.
  • These results led to a recommendation for accelerated FDA approval.

Conclusions:

  • Brentuximab vedotin exhibits potent single-agent activity for treating relapsed Hodgkin lymphoma and ALCL.
  • Ongoing clinical trials are evaluating the incorporation of brentuximab vedotin into frontline treatment regimens.
  • This highlights a significant advancement in CD30-targeted cancer therapy.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.